08:01 AM EDT, 10/15/2024 (MT Newswires) -- MeiraGTx Holdings ( MGTX ) said Tuesday that data from a study of its experimental Parkinson's disease treatment, AAV-GAD, showed a statistically significant improvement in motor examination score in the high-dose group compared with no significant change in the sham or low-dose groups.

The drug also significantly improved the disease-specific, patient-reported quality of life measures in both the high and low-dose groups, with no substantial change in the sham group.

AAV-GAD was safe and well tolerated, with no serious adverse events reported.

The company plans to use the study's data for discussions with regulators in the US, Europe, and Japan to initiate a global Phase 3 study.

MeiraGTx ( MGTX ) shares jumped more than 12% in premarket trading.

Price: 5.2100, Change: +0.57, Percent Change: +12.28